Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

Lung, Respiratory and Thoracic Cancer

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial

J Thorac Oncol

Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML

doi: 10.1016/j.jtho.2024.09.1381

Lung, Respiratory and Thoracic Cancer

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

JTO Clin Res Rep

Schmid S, Holer L, Gysel K, Koster KL, Rothschild SI, Boos LA, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur WD, Allemann A, Waibel C, Von der Mühll-Schill C, Früh M, Mauti LA

doi: 10.1016/j.jtocrr.2024.100735

Central Nervous System Tumors

The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wildtype and -mutant lower grade gliomas

Neuro Oncol

Kinslow CJ, Roy S, Iwamoto FM, Brown PD, DeStephano DM, Canoll PD, Qureshi SS, Gallito M, Sisti MB, Bruce JN, Horowitz DP, Kachnic LA, Neugut AI, Yu JB, Mehta MP, Cheng SK, Wang TJC

doi: 10.1093/neuonc/noae102

Leukemia

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Lancet Oncol

Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B

doi: 10.1016/S1470-2045(24)00196-7

Lung, Respiratory and Thoracic Cancer

Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: Real-world outcomes from the GuardantINFORM database

J Thorac Oncol

Parikh K, Dimou A, Leventakos K, Mansfield AS, Shanshal M, Wan Y, Lin HM, Vincent S, Elliott J, Bonta IR

doi: 10.1016/j.jtho.2024.07.009

Lung, Respiratory and Thoracic Cancer

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Lung Cancer

Pons-Tostivint E, Ezzedine R, Goronflot T, Crequit P, Chatellier T, Raimbourg J, Bennouna J, Giroux Leprieur E, Porte M

doi: 10.1016/j.lungcan.2024.107887

EHA 2024

Leukemia

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

EHA 2024

Leukemia

RESONATE-2: Sustained survival benefit with first-line ibrutinib in older patients with CLL with up to ten years of follow-up

Lung, Respiratory and Thoracic Cancer

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study

JTO Clin Res Rep

Moliner L, Zellweger N, Schmid S, Bertschinger M, Waibel C, Cerciello F, Froesch P, Mark M, Bettini A, Häuptle P, Blum V, Holer L, Hayoz S, Früh M, Ahmed S, Bhagani S, Steele N, Gray HL, Robinson SD, Davidson M, Cox S, Khalid T, Geldart TR, Nolan L, Scott DC, Hennah L, Newsom-Davis T, Rathbone E, Handforth C, Denton A, Merchant S, Blackhall F, Mauti LA, Califano R, Rothschild SI

doi: 10.1016/j.jtocrr.2024.100744

Related content

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes from the Phase 3 POSEIDON Trial

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wildtype and -mutant lower grade gliomas

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: Real-world outcomes from the GuardantINFORM database

Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

RESONATE-2: Sustained survival benefit with first-line ibrutinib in older patients with CLL with up to ten years of follow-up

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study